Navigation Links
CenSlide 2000 system

ProductsCenSlide 2000 system
Company Iris Sample Processing (formerly StatSpin, Inc.)
Item CenSlide 2000 system
Features 
  • Acceleration Time: 15 seconds to 95% of speed
  • Warranty 1 Year
  • Bleach-compatible molded plastic base, cover and rotor.
  • Microprocessor-controlled operation.
  • Cover interlock system.
  • Gasket sealed chamber.
  • Tachometer window for speed verification.
Tube Specifications
  • Material: Clarified Polypropylene
  • Capacity: 2 - 5 mL
  • Viewing Area: 7.9 mm x 10.7 mm
  • Viewing Area: 7.9 mm x 10.7 mm
Description CenSlide 2000; a unique closed system for performing fast, clean, safe and accurate microscopic urinalysis. The CenSlide 2000 system is microprocessor controlled to automatically spin CenSlide tubes at a preset speed for one minute. At the end of the cycle, the urine sediment is distributed evenly across the viewing area for microscopic analysis. The CenSlide Urinalysis System controls inherent variations in microscopic examination by standardizing urine sediment volume, centrifuge conditions and technique while significantly reducing total time for analysis.
Info Iris Sample Processing (formerly StatSpin, Inc.)
Customer Service: (800) STATSPIN (782-8774)
Web site: http://www.statspin.com

Related medicine products :

1. SuperVu 2.5x Galilean system
2. SuperVu 2.0x Galilean system
3. SuperVu 3.0x Galilean system
4. Catalyst system
5. Headband headlight system
6. Sweatband headlight system
7. Headband headlight system (10-75 mm variable spot)
8. Headband headlight system (100 mm fixed spot)
9. IMx system
10. TDx system
11. Long system Ventriculoscope
It is designed for rigid skeletal fixation. These pins are constructed of stainless steel and can be removed for sterilization and reuse....
It is designed for rigid skeletal fixation. These pins are constructed of stainless steel and can be removed for sterilization and reuse....
It is designed for rigid skeletal fixation. These pins are constructed of stainless steel and can be removed for sterilization and reuse....
... designed for rigid skeletal fixation, ... freedom in positioning the fixation ... fixation is designed for the ... positions. Craniotomies can be performed ...
Medicine Products:
(Date:6/19/2013)... 19, 2013 Brightree LLC , ... software solutions for the post-acute care industry, has been ranked ... the Healthcare Informatics 100 (HCI 100) list. This ... the U.S. in terms of revenue during the last fiscal ... rate of 85% annually, and the company has built its ...
(Date:6/19/2013)... AZ (PRWEB) June 19, 2013 Guests at ... healthy, wealthy and wise even if they don’t go to ... does require some early thought. , Crafty ... when they take advantage of the pet-friendly Scottsdale Paradise Valley ... Package . With at least 14 days advance notice, guests ...
(Date:6/19/2013)... Boca Raton, FL (PRWEB) June 19, 2013 ... spoke about the positive changes and growth that has occurred ... his nationwide travel club. , Shuman said, "Travel Services has ... program to heights beyond belief. Membership is up, even ... agents to meet the demands of members." , Having been ...
(Date:6/19/2013)... Amerinet, Inc, a leading national ... to help Pacific Medical Centers implement a comprehensive ... than 17 percent over the organization’s previous clinical ... economies of scale and process standardization are two ... multi-site providers,” said Shawn Padilla, director of supply ...
(Date:6/19/2013)... lateral sclerosis (ALS), also known as Lou Gehrig,s Disease, ... classified into four distinct stages, report pathologists with the ... in the Annals of Neurology . This post-mortem ... for the first time, how the fatal degenerative disease ... nervous system to other regions of brain and spinal ...
Breaking Medicine News(10 mins):Health News:Brightree Debuts on List of Top 100 Healthcare Technology Companies 2Health News:Brightree Debuts on List of Top 100 Healthcare Technology Companies 3Health News:Plan Ahead and Save Big With New Deal From Residence Inn Scottsdale Paradise Valley 2Health News:Plan Ahead and Save Big With New Deal From Residence Inn Scottsdale Paradise Valley 3Health News:Plan Ahead and Save Big With New Deal From Residence Inn Scottsdale Paradise Valley 4Health News:Former Owner Eric Shuman Endorses New Owners and Changes Made in Last Year Since Shuman Sold Travel Services Center at Member Conference 2Health News:Amerinet Partners with ARAMARK Healthcare Technologies to Help Pacific Medical Centers Save 17 Percent and Better Manage System-Wide Equipment Program 2Health News:Staging system in ALS shows potential tracks of disease progression, Penn study finds 2
... is a Wholly Owned Subsidiary of Shamir, KIBBUTZ ... SHMR ) ("Shamir"), a leading provider of innovative,products ... it has,signed an agreement yesterday, June 30, 2008, pursuant ... ("Altra") from its minority,shareholder. Prior to this transaction, Shamir ...
... Conn., July 1 UTC Power, a United,Technologies Corp. ... supply St.,Helena Hospital in California,s Napa Valley with its ... will be in full,production in the summer of 2009., ... hospital and,part of Adventist Health, a not-for-profit health care ...
... July 1 Opus Healthcare Solutions, Inc.,a ... has named Ray,Bechtold, CPA, as controller. Based ... responsible for overseeing all accounting and financial,administrative ... (Logo: http://www.newscom.com/cgi-bin/prnh/20080325/LATU040LOGO ), Bechtold joined ...
... RGEN ) announced today that Dr. Alfred L. ... Dr. Goldberg is currently a Professor of,Cell Biology at ... in,particular for elucidating the structure and function of the ... destroyed in,cells. In addition, he has made major contributions ...
... pain. This was the result of the analysis ... her colleagues and published in the current edition ... Int, 2008; 105[24]: 441-8). , http://www.aerzteblatt.de/v4/archiv/pdf.asp?id=60552 ... more than 8000 private persons in the course ...
... staying asleep increase as women go through menopause ... Waking up earlier than planned also increases through ... The study is published in the July 1 ... "Sleep difficulties, especially problems staying asleep, are relatively ...
Cached Medicine News:Health News:Shamir Optical Industry Purchases Remaining 49% of Altra Trading GmbH 2Health News:Shamir Optical Industry Purchases Remaining 49% of Altra Trading GmbH 3Health News:St. Helena's Hospital Orders New Model 400kW Fuel Cell From UTC Power 2Health News:Opus Healthcare Solutions Names Ray Bechtold as Controller 2Health News:Repligen Elects Alfred L. Goldberg, Ph.D. to the Board of Directors 2Health News:Repligen Elects Alfred L. Goldberg, Ph.D. to the Board of Directors 3Health News:Sleep problems associated with menopause vary among ethnic groups 2
(Date:6/19/2013)... June 19, 2013   Voices Against Brain Cancer ... cure for brain cancer, today announced that it has ... support the clinical investigation of Toca 511 & Toca ... glioma brain cancer (Grade 3 or Grade 4).  Tocagen ... for advanced cancer, with an initial focus on brain ...
(Date:6/19/2013)...   Nektar Therapeutics (Nasdaq: NKTR ) ... (HAL) study for NKTR-181, a first-in-class, opioid analgesic ... This slow rate of entry is designed to reduce the ... to current opioid analgesics. 1 In the study data ... placebo in "drug liking" and "feeling high" scores and had ...
(Date:6/19/2013)... ZIONA, Israel , June 19, ... that results from a phase I study in volunteers, ... advanced Parkinson,s patients, of ND0612, were presented at the ... ND0612 is a proprietary levodopa/carbidopa liquid drug formula under ... patch that would maintain constant levodopa plasma concentrations. ...
Breaking Medicine Technology:Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 2Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 2Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 4Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 5Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 6Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 7Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 8Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 9NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 2NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 3NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 4NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 5NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 6